Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Accenture
Merck
US Department of Justice
Teva
Novartis
Chubb
Healthtrust
McKinsey
Citi

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,637,320

« Back to Dashboard

Summary for Patent: 5,637,320
Title: Controlled absorption naproxen formulation for once-daily administration
Abstract:A once-daily naproxen formulation for oral administration having a first portion of the naproxen as a multi-particulate pellet form, each pellet having a core of naproxen or a pharmaceutically acceptable salt thereof in association with an organic acid, the core being surrounded by a multi-layer membrane and optionally a second portion of naproxen formulated to release the drug promptly following oral administration.
Inventor(s): Bourke; Edward A. (Athlone, IE), Mulligan; Seamus (Athlone, IE)
Assignee: Elan Corporation, PLC (Athlone, IE)
Application Number:08/227,566
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 5,637,320

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,637,320

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Ireland149/90Jan 15, 1990

International Patents Family Members for US Patent 5,637,320

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 126055 ➤ Sign Up
Australia 639519 ➤ Sign Up
Australia 6933291 ➤ Sign Up
Canada 2034096 ➤ Sign Up
Germany 69111832 ➤ Sign Up
Denmark 0438249 ➤ Sign Up
European Patent Office 0438249 ➤ Sign Up
Spain 2075338 ➤ Sign Up
Greece 3017633 ➤ Sign Up
Ireland 66933 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Chinese Patent Office
Teva
Daiichi Sankyo
Medtronic
US Army
Julphar
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot